ImmunoGen Inc. (IMGN) Drops 6.75% on January 27

Equities Staff |

ImmunoGen Inc. (IMGN) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 6.75% to $8.56, a loss of $-0.62 per share. Starting at an opening price of $9.15 a share, the stock traded between $8.52 and $9.50 over the course of the trading day. Volume was 995,333 shares over 8,541 trades, against an average daily volume of 1.16 million shares and a total float of 86.98 million.

The losses send ImmunoGen Inc. down to a market cap of $744.59 million. In the last year, ImmunoGen Inc. has traded between $19.43 and $6.02, and its 50-day SMA is currently $12.22 and 200-day SMA is $12.57.

Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

ImmunoGen Inc. is based out of Waltham, MA and has some 317 employees. Its CEO is Daniel M. Junius.

For a complete fundamental analysis analysis of ImmunoGen Inc., check out Equities.com’s Stock Valuation Analysis report for IMGN. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IGEN Networks Corp.

iGen Networks Corp is engaged in investing in and managing for growth private high-tech companies that offer products and services in the domains of wireless broadband, software as a service,…

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…